Collaboration will provide BioFocus customers with compound screening and profiling services using Almac’s Flexyte FLT assays
BioFocus and Almac have initiated a collaboration that will provide BioFocus customers with compound screening and profiling services using Almac’s Flexyte fluorescence lifetime (FLT) assays. FLT as a reading modality offers a robust, antibody-free, homogeneous assay platform that enables the user to avoid interference from fluorescent compounds within a screening library.
BioFocus has launched an FLT screening and profiling service utilising the Flexyte assay platform and now offers campaigns against targets including proteases, phosphatases and kinases.
The unique properties of FLT have also been harnessed to open up access to previously inaccessible epigenetics target classes. Several approaches can be taken using the Flexyte platform, including fragment-based screens and kinetic profiling.
‘Being able to incorporate FLT in our service offering enables BioFocus to provide clients an approach to screening and profiling that will unlock significant potential within their drug discovery efforts,’ said Dr Kate Hilyard, vp biological sciences, BioFocus.
‘We are delighted that BioFocus has chosen to add our Flexyte platform to their service offering,’ added Dr Stephen Barr, president and managing director of Almac Sciences. ‘We feel that this will allow a broad range of drug discovery groups access to the power of FLT.’